Product Overview

Sifasi Aqua 5000 is a sterile, lyophilized preparation of human chorionic gonadotropin (HCG) supplied by Serum Institute India. Each vial contains 5000 International Units (IU) of HCG in a 1 ml solution, intended for intramuscular or subcutaneous injection. The product is indicated for the treatment of female infertility linked to ovulatory dysfunction. Packaged in a sealed glass vial, each carton offers three, six, or nine vials, providing flexibility for clinical protocols. The medication is shipped under refrigerated conditions to preserve potency, with an estimated delivery time of six to fifteen days after ordering. The lyophilized form ensures stability at room temperature for up to 24 months when stored properly.

What is Sifasi Aqua 5000

Human chorionic gonadotropin (HCG) is a glycoprotein hormone produced by the placenta during early pregnancy. Clinically, HCG mimics luteinizing hormone (LH) and stimulates the ovaries to produce estrogen and mature ovarian follicles. Sifasi Aqua 5000 delivers a precise 5000–IU dose per vial, enabling physicians to reliably trigger ovulation in controlled ovarian stimulation protocols such as in‐vitro fertilization (IVF). The hormone is extracted, purified, and freeze‐dried under Good Manufacturing Practice (GMP) standards, ensuring batch‐to‐batch consistency and therapeutic safety. Its structural similarity to native LH provides a predictable pharmacodynamic profile. Because the hormone remains active for approximately one to two days, timing of administration is critical to synchronize follicular rupture and maximize oocyte retrieval success. Its standardized IU measurement eliminates the need for dose conversion, simplifying prescription practices for clinicians.

Uses and Benefits

The primary clinical application of Sifasi Aqua 5000 is to induce final follicular maturation in women undergoing controlled ovarian stimulation for assisted reproduction. A single injection of 5000–IU is typically administered when ultrasound monitoring shows follicles of 18–20 mm and estradiol levels meet protocol thresholds, prompting a LH–like surge that triggers ovulation. In addition to supporting IVF cycles, HCG can be used in the management of hypogonadotropic hypogonadism, offering a hormone‑replacement approach that restores menstrual regularity. The standardized potency of Sifasi Aqua 5000 reduces dosing errors, enhances reproducibility across treatment cycles, and contributes to higher-quality embryo development, ultimately increasing the probability of a successful pregnancy. Clinical studies have demonstrated increased pregnancy rates when HCG is used as a trigger compared with placebo in properly selected populations (see National Institutes of Health).

How It Works

When administered, HCG binds to receptors on the ovarian theca cells, stimulating the production of androgens that are subsequently converted to estrogen by aromatase enzymes in granulosa cells. This hormonal cascade drives rapid follicular growth and culminates in a LH‑like surge that induces ovulation. The exogenous HCG replicates the endogenous LH peak, providing a reliable trigger for egg release. Its half‑life of roughly 24–36 hours allows clinicians to schedule oocyte retrieval approximately 34–36 hours after injection, optimizing fertilization conditions. Because HCG is structurally identical to native LH, its pharmacodynamic effects are well understood and predictable. This mechanism enables precise control over the timing of egg maturation, which is essential for synchronizing retrieval with sperm availability and laboratory conditions.

Dosage Guidelines

Dosage of Sifasi Aqua 5000 must be individualized according to the patient’s ovarian reserve, response to prior stimulation, and the specific assisted reproduction protocol. A common regimen involves a single intramuscular or subcutaneous injection of 5000–IU once follicular diameters reach 18–20 mm on ultrasound and estradiol levels are adequate. Some protocols employ a split dose of 2500–IU followed by a second 2500–IU dose 24 hours later to fine‑tune ovulation timing. Clinicians should monitor follicular growth and hormone levels closely, adjusting the timing of the HCG trigger to no later than 36 hours before planned oocyte retrieval, thereby maximizing the chance of successful fertilization while minimizing the risk of ovarian hyperstimulation. For detailed prescribing information, refer to the U.S. Food and Drug Administration label. Physicians may adjust the trigger point based on individualized risk assessments and patient tolerance.

Side Effects

Most patients tolerate Sifasi Aqua 5000 well, but some may experience mild and transient adverse effects. Common side effects include irritation or redness at the injection site, mild headache, and occasional abdominal discomfort or bloating. Less frequently, the medication can provoke ovarian hyperstimulation syndrome (OHSS), a condition marked by rapid weight gain, severe pelvic pain, and shortness of breath, which requires prompt medical evaluation. Rarely, allergic reactions such as rash, itching, or respiratory distress may occur. Patients are advised to report any unexpected or severe symptoms to their healthcare provider immediately, and regular laboratory monitoring is recommended to detect early signs of OHSS. Long‑term safety data indicate a low incidence of serious adverse events when the drug is used according to approved protocols.

Warnings and Precautions

Sifasi Aqua 5000 is contraindicated in individuals with a known hypersensitivity to HCG or any excipients in the formulation. It should not be used in patients with hormone‑sensitive cancers, unresolved ovarian cysts, or active pelvic inflammatory disease. Prior to treatment, a comprehensive medical history and physical examination are essential to identify conditions that could be exacerbated by hormonal stimulation, such as thromboembolic disorders. Pregnant women must avoid HCG therapy, as it may interfere with pregnancy testing and management. The product must be stored refrigerated (2‑8 °C) and protected from light until use. Clinicians should exercise caution when prescribing to patients with severe cardiovascular or renal impairment. Healthcare providers should counsel patients about the importance of adhering to storage recommendations to maintain potency.

Frequently Asked Questions

1. What storage conditions are required for Sifasi Aqua 5000? Store the vial in a refrigerator between 2 °C and 8 °C, protect it from light, and do not freeze. Once reconstituted, the solution can be kept at room temperature for up to 24 hours if used promptly.
2. When should the HCG injection be administered relative to oocyte retrieval? The injection is typically given when the leading follicle measures 18–20 mm in diameter and hormone levels are adequate, and it should occur no later than 36 hours before the scheduled egg collection to ensure optimal timing.
3. Can Sifasi Aqua 5000 be used in male fertility treatment? HCG is occasionally prescribed off‑label for male hypogonadism to stimulate testosterone production, but its primary FDA‑approved indication is female infertility; any off‑label use should be supervised by a qualified physician.
4. Is it safe to use Sifasi Aqua 5000 while breastfeeding? Breastfeeding individuals should avoid HCG therapy unless a physician determines the benefits outweigh potential risks; the hormone may be excreted in milk and could affect infant development.
5. Where can I find more detailed information about HCG therapy? Comprehensive guidance is available from the National Institutes of Health (National Institutes of Health) and the U.S. Food and Drug Administration (U.S. Food and Drug Administration), as well as MedlinePlus (MedlinePlus).

Related Products

• CB-Lin (Cabergoline)
• Meprate 10 mg (Medroxyprogesterone)
• Sicriptin 2.5 mg Tablets (Bromocriptine)
• Sicriptin 1.25 mg Tablets (Bromocriptine)
• Sicriptin (Bromocriptine)
• Bromocriptine 1.25 mg (Generic)
• Bromocriptine 2.5 mg (Generic)
• ZyhCG 10000 (HCG 10000iu)
• ZyhCG 5000 (HCG 5000iu)
• ZyhCG 2000 (HCG 2000iu)
• Clomiphene 50 mg (Generic)
• Clomiphene 100 mg (Generic)